- |||||||||| pegylated liposomal doxorubicin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Biomarker, Trial completion date, Trial primary completion date: Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma (clinicaltrials.gov) - May 17, 2021 P=N/A, N=24, Recruiting, The constructed prediction model may be valuable for predicting the occurrence of MSHFS in patients. Trial completion date: Jan 2021 --> Dec 2022 | Trial primary completion date: Jan 2021 --> Dec 2021
- |||||||||| pegylated liposomal doxorubicin / Generic mfg.
Journal: Premature Drug Release from Polyethylene Glycol (PEG)-Coated Liposomal Doxorubicin via Formation of the Membrane Attack Complex. (Pubmed Central) - May 15, 2021 Here, we show that anti-PEG IgG and IgM antibodies bind to PEG molecules on the surface of PEG-coated liposomal doxorubicin (Doxil, Doxisome, LC-101, and Lipo-Dox), resulting in complement activation, formation of the membrane attack complex (C5b-9) in the liposomal membrane, and rapid release of encapsulated doxorubicin from the liposomes...Doxorubicin release of up to 40% was also observed in rats treated with anti-PEG IgG and PEG-coated liposomal doxorubicin. Our results demonstrate that anti-PEG antibodies can disrupt the membrane integrity of PEG-coated liposomal doxorubicin through activation of complement, which may alter therapeutic efficacy and safety in patients with high levels of pre-existing antibodies against PEG.
- |||||||||| pegylated liposomal doxorubicin / Generic mfg.
Journal: Bispecific Antibody (HER2 × mPEG) Enhances Anti-Cancer Effects by Precise Targeting and Accumulation of mPEGylated Liposomes. (Pubmed Central) - May 15, 2021 HER2 ×mPEG BsAb can simultaneously bind to HER2-high expressing MCF7/HER2 tumor cells and mPEG molecules on mPEG-liposomal doxorubicin (Lipo-Dox)...These results indicate that HER2 × mPEG BsAb can enhance tumor accumulation of mPEG-liposomes to improve the therapeutic efficacy of combination treatment. Anti-mPEG scFv can be fused to any kind of targeted antibody to generate BsAbs to actively attract mPEG-drugs and improve anti-cancer efficacy.
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, P2b data, Journal, PD(L)-1 Biomarker, IO biomarker: ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer. (Pubmed Central) - May 15, 2021 P2b These studies may uncover biomarkers or mechanisms of efficacy and resistance, thereby informing the development of novel combinatory regimes and of personalised biomarker-based therapy. Trial registration NCT03409198, Jan 24th 2018; https://clinicaltrials.gov/ct2/show/record/NCT03409198.
- |||||||||| pegylated liposomal doxorubicin / Generic mfg.
Clinical, Journal: Complement Activation: A Potential Threat on the Safety of Poly(ethylene glycol)-Coated Nanomedicines. (Pubmed Central) - May 15, 2021 provide in vitro and in vivo evidence for monoclonal anti-poly(ethylene glycol) (anti-PEG) antibody-triggered, complement terminal complex-mediated damage to PEGylated liposomal doxorubicin, entailing the release of the encapsulated drug from the vesicles...The possibility of a destructive attack of the complement system on the liposome drug carrier may have safety implications in patients displaying high levels of preformed anti-PEG antibodies. In this Perspective, we summarize the experimental and clinical data highlighting the relationships among the above adverse immune phenomena and the options available for reducing the risk of immune damage caused by PEGylated nanomedicines.
- |||||||||| Journal: A novel targeted delivery system for drug-resistant hepatocellular carcinoma therapy. (Pubmed Central) - May 15, 2021
This finding suggests that HCSP4-Lipo-DOX-miR101 can cause DOX-resistant HCC cell death and growth inhibition based on the targeting of MDR-related genes by miR-101. In conclusion, the findings of this study suggest that HCSP4-Lipo-DOX-miR101 may serve as a promising novel targeted delivery system for improving the therapeutic efficiency of drug-resistant hepatocellular carcinoma.
- |||||||||| pegylated liposomal doxorubicin / Generic mfg.
Journal: Compositional inhomogeneity of drug delivery liposomes quantified at the single liposome level. (Pubmed Central) - May 15, 2021 Here we image individual liposomes using confocal microscopy to quantify that liposomal drug delivery formulations, including multiple component mixtures mimicking Doxil, display more than 10-fold variation in their relative lipid composition...Additionally, we quantified how this degree of compositional inhomogeneity was modulated by liposome preparation method, the saturation state of the membrane lipid, and whether anti-fouling polyethylene glycol (PEG) conjugated lipids were added to the initial lipid mix or inserted after liposome formation. We believe the insights into the factors governing the degree of inhomogeneity offers the possibility for producing more uniform liposomal drug delivery systems, potentially increasing their therapeutic efficacy.
- |||||||||| pegylated liposomal doxorubicin / Generic mfg.
Journal: Person-Specific Biomolecular Coronas Modulate Nanoparticle Interactions with Immune Cells in Human Blood. (Pubmed Central) - May 15, 2021 For comparison, clinically relevant PEGylated doxorubicin-encapsulated liposomes (Doxil) (74 nm in diameter) showed significant variance in association with monocytes and B cells across all plasma donors studied...We identified key immunoglobulin and complement proteins that explicitly enriched or depleted within the corona and which strongly correlated with the cell association pattern observed across the 23 donors. This study demonstrates how plasma variance in healthy individuals significantly influences the blood immune cell interactions of nanoparticles.
- |||||||||| pegylated liposomal doxorubicin / Generic mfg.
Journal: High Intensity Focused Ultrasound-Responsive and Ultrastable Cerasomal Perfluorocarbon Nanodroplets for Alleviating Tumor Multidrug Resistance and Epithelial-Mesenchymal Transition. (Pubmed Central) - May 15, 2021 The oxygen release and temperature elevation jointly relieved tumor hypoxia and alleviated MDR, which greatly enhanced the drug therapeutic efficacy as compared to clinically used doxorubicin and Doxil...When "D-vPCs-O + M-HIFU" was utilized as a neoadjuvant chemotherapy, nanodroplets down-regulated heat shock proteins, reducing tumor relapse after the high-temperature HIFU (H-HIFU)-mediated hyperthermia ablation. The chemo-hyperthermia therapy totally eradicated tumors without any relapse or metastasis, providing a promising way to treat the triple-negative breast cancer, which is highly malignant, easily metastatic, and lacks effective treatments.
- |||||||||| pegylated liposomal doxorubicin / Generic mfg.
Journal: Unique flower-like Cur-metal complexes loaded liposomes for primary and metastatic breast cancer therapy. (Pubmed Central) - May 15, 2021 Superior performances of Cur-copper complexes liposomes were observed in improving Cur stability, promoting apoptosis, inhibiting the proliferation and angiogenesis, therefore enhancing therapeutic effect for primary and metastatic breast cancer. Overall, the current work highlights the potentially significant development value of Cur-M liposomes as an injectable agent for cancer treatment, even superior to the commercial agent Doxil.
- |||||||||| Onpattro (patisiran) / Alnylam, Sanofi
Clinical, Review, Journal: Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines. (Pubmed Central) - May 1, 2021 We also discuss the physicochemical properties required for specific applications, highlight the differences in requirements for the delivery of different cargos, and introduce current challenges that need further development. This review serves as a useful guideline for designing new lipid nanoparticles for both preventative and therapeutic vaccines including immunotherapies.
- |||||||||| pegylated liposomal doxorubicin / Generic mfg., busulfan / Generic mfg.
[VIRTUAL] Exploring the Use of a DSG2-Targeting Adenoviral Junction Opener-Doxorubicin Conjugate for Hematopoietic Stem Cell Depletion () - Apr 30, 2021 - Abstract #ASGCT2021ASGCT_708; Preliminary experiments of JOC-Doxil in DSG2-transgenic mice suggest a cytotoxic impact on certain HSCs (LSK cells) in the bone marrow, and JOC-Doxil administration in M. fascicularis indicated a close colocalization of DSG2-expressing HSC and JO in the bone marrow, indicating JOC-Doxil's specific localization to its targets. An HSC-specific cytotoxic agent such as JOC-Doxil could alleviate many of the toxic side effects caused by broad lymphotoxins or radiation used in hematopoietic cell depletion and represents a promising development in the field of hematopoietic stem cell transplantation.
- |||||||||| pegylated liposomal doxorubicin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Journal: Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs. (Pubmed Central) - Apr 28, 2021 Moreover, cancer cell-derived exosomes were engineered to carry Doxil (a common chemotherapy drug), known as D-exo, were used to detect their target and therapeutic efficacy as anti-cancer drugs...Exosome proteome array analysis revealed distinct integrin expression patterns, which might shed light on the underlying mechanisms that explain the exosomal cancer-homing behavior. Here we demonstrate that the exosomes' ability to target the parent cancer is a phenomenon that opens up new ways to devise targeted therapies to deliver anti-tumor drugs.
- |||||||||| Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion, Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date: Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Apr 22, 2021 P2, N=240, Recruiting, Trial completion date: Feb 2028 --> Mar 2024 | Trial primary completion date: Mar 2027 --> Mar 2022 Trial completion date: Jun 2021 --> Jul 2023 | Trial primary completion date: Jun 2021 --> Jul 2022
|